GlassScriptPhysician profile
Samuel S Lee
NPI 1710320718
$4,227.25
in general payments reported to CMS, 2019-2025
45 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $493 · 2024: $2,768 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.05 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,235.61 | 2024-2025 | Mitraclip, Proclaim |
| Novartis Pharmaceuticals Corporation | $568.84 | 2023-2025 | |
| Pfizer INC. | $274.89 | 2023-2025 | |
| Janssen Biotech, INC. | $213.15 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $174.22 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $155.00 | 2024 | Myrisk |
| Daiichi Sankyo INC. | $134.50 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $102.70 | 2023-2024 | Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $83.89 | 2024-2025 | Keytruda |
| Astellas Pharma US INC | $81.51 | 2023-2025 | Cresemba, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $81.48 | 2023-2025 | Calquence, Enhertu |
| Beigene USA, INC. | $76.78 | 2022-2025 | Brukinsa |
| Argenx US, INC. | $74.55 | 2025 | |
| Array Biopharma INC | $70.08 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Alexion Pharmaceuticals, INC. | $67.46 | 2023-2024 | Ultomiris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.